QTTB (Q32 Bio) Shareholder Yield % : -3.27% (As of Mar. 2026)


QTTB Q32 Bio Inc QTTB
17 GF Score
Price $12.84
! 6 Warning Signs
View Full Analysis

What is Q32 Bio Shareholder Yield %?

Q32 Bio QTTB -1.72% 17 Shareholder Yield % is -3.27% as of Mar. 2026. GuruFocus rates QTTB with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,295 Biotechnology companies, Q32 Bio ranks worse than 55.75% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Q32 Bio's Shareholder Yield % was -3.27%.


Q32 Bio  (NAS:QTTB) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Q32 Bio Shareholder Yield % Related Terms


Q32 Bio Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Q32 Bio's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio Shareholder Yield % Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
0.00 0.00 0.00 -26.92 4.95

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.31 89.06 37.81 4.95 -7.77

QTTB vs CAMP, CDXS, KROS: Shareholder Yield % Comparison

For the Biotechnology subindustry, Q32 Bio's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Shareholder Yield % falls into.


QTTB
17GF Score
Q32 Bio Inc QTTB
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio Shareholder Yield % Calculation

Q32 Bio's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-11.03 %+3.26 %
=-7.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -3.27% mean?
Q32 Bio (QTTB) has a Shareholder Yield % of -3.27% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #722 out of 1295 companies in the Biotechnology industry, placing it in the top 55.8%.
Is Q32 Bio's Shareholder Yield % too high?
Q32 Bio's current Shareholder Yield % is -3.27%. Based on the distribution chart, Q32 Bio ranks #722 out of 1295 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Shareholder Yield % compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #722 out of 1295 companies for Shareholder Yield %. This places Q32 Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Q32 Bio and its competitors. Q32 Bio's current Shareholder Yield % is -3.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (QTTB) has a current Shareholder Yield % of -3.27%. The current Shareholder Yield % is -3.27%. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Q32 Bio (QTTB), the current Shareholder Yield % is -3.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges DB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for QTTB

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.84
Price